Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.
Researchers explored the role of endogenous retrovirus (ERV) reactivation in the aging process.
Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) -; the most common form of the chronic autoimmune disease lupus.
Scientists from the Institut Pasteur, Université Paris Cité, the CNRS and the Collège de France have used paleogenomics to trace 10,000 years of human immune system evolution.
A new report throws light on SARS-CoV-2 breakthrough infections in patients with certain joint diseases or musculoskeletal conditions who are on rituximab and compares the severity of COVID-19 outcomes in these patients whilst identifying potential risk factors for severe outcomes.
The Lupus Research Alliance (LRA) proudly announces the two outstanding recipients of the 2022 Distinguished Innovator Award (DIA): Hongbo Chi, PhD, and Joseph Craft, MD.
Engineered immune cells, known as CAR T cells, have shown the world what personalized immunotherapies can do to fight blood cancers.
The Lupus Research Alliance and its affiliate Lupus Therapeutics presented data at ACR Convergence 2022 with results showing the effectiveness of a pilot peer education program called the Patient Advocates for Lupus Studies (PALS), in increasing knowledge, perception, and willingness among people with Systemic Lupus Erythematosus (SLE) to participate in clinical trials.
Tyrosine kinases are enzymes that play central roles in signaling by cytokines involved in the pathogenesis of autoimmune diseases, including lupus.
Type I interferon (IFN) is a powerful immune activator that is present at high levels in the majority of patients with lupus, an autoimmune disease. In Arthritis & Rheumatology, researchers report positive results from the first placebo-controlled long-term trial of anifrolumab-;a human monoclonal antibody that targets the type I IFN receptor-;in patients with lupus.
New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual scientific meeting, found that the recommended weight-based or non-weight-based dose of hydroxychloroquine led to more hospitalizations for flares among patients with systemic lupus erythematosus
Researchers identified a genetic association signal, via genome-wide association studies, between severe COVID-19 with systemic lupus erythematosus, an autoimmune disease.
In 2022, EULAR - the European Alliance of Rheumatology Associations - published new recommendations regarding lifestyle behaviors and work participation to prevent progression of rheumatic and musculoskeletal diseases (RMDs).
Researchers gathered empirical evidence that past pandemics due to infectious pathogens shaped the present-day susceptibility of humans to diseases, such as autoimmune diseases.
Researchers assess the role of neutrophil extracellular traps (NETs) in systemic autoimmune and autoinflammatory disorders.
A multi-institutional team of scientists, led by researchers at Weill Cornell Medicine's Gale and Ira Drukier Institute for Children's Health, have received a five-year $8.297 grant to continue funding a Center for Lupus Research.
In a new study, researchers outlined the synthesis and the possible mechanism of action (MOA) of two potential severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) repurposing drug candidates.
A new review discussed the applications of single-cell ribonucleic acid sequencing (scRNA-seq) in understanding autoimmune disorders.
Researchers explore the potential association between SARS-CoV-2 infection and immune-mediated inflammatory diseases.
In a new study, researchers reviewed existing literature on the biomedical waste source, elements, and the recent upsurge of microplastics during the SARS-CoV-2 pandemic.
Despite recent advancements in our knowledge of the pathogenic mechanisms of ulcerative colitis, there is still a considerable unmet medical need for the treatment of ulcerative colitis.